Treatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer
Küçük Resim Yok
Tarih
2013
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Treatment options for patients with non-muscle invasive bladder cancer (NMIBC) refractory to intravesical bacillus Calmette-Guérin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NMIBC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this point radical cystectomy is the standard treatment of choice. If this option is not feasible, intravesical chemotherapy with docetaxel or gemcitabine, the combination of BCG and interferon (INF)-á or device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are some of the candidates for further treatment.
Açıklama
Anahtar Kelimeler
BCG failure, Itravesical therapy, Non-muscle invasive bladder cancer
Kaynak
Archivos Espanoles de Urologia
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
66
Sayı
9